Yuwen Chen

Dr. Yuwen Chen

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
SZSiwen Zhang
Siwen Zhang
YLYujun Li
Yujun Li
WLWenxi Liu
Wenxi Liu
QCQi Chu
Qi Chu
SWShasha Wang
Shasha Wang
YCYuwen Chen
Yuwen Chen
Artificial intelligence (AI) and medical devices are increasingly integrated, reshaping global diagnostic paradigms. However, the adaptive learning and opaque nature of AI technologies pose significant challenges to traditional regulatory frameworks. In response, regulatory bodies worldwide, including the U.S., EU, China, Japan, and South Korea, have initiated various policies to address the unique risks posed by AI medical devices (AIMD). These efforts aim to balance innovation with patient safety, yet gaps remain in harmonizing standards across regions and ensuring comprehensive oversight. This study provides a comprehensive analysis of the regulatory policies for AIMD from 2015 to 2025 across key global regions. We examine the evolution of these policies, the academic research progress, the limitations of existing regulations, and emerging trends. By reviewing relevant legislation and literature, this paper offers valuable insights for researchers, manufacturers, and regulators to foster the development of robust regulatory frameworks for AIMD.

9 June 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
YWYanyi Wei
Yanyi Wei
JZJialin Zhu
Jialin Zhu
JQJiahui Qiao
Jiahui Qiao
DZDawei Zhang
Dawei Zhang
YCYuwen Chen
Yuwen Chen
In 2016, China began to execute the consistency evaluation policy of generic drugs. Many scholars believed that the policy would stimulate pharmaceutical firms to increase R&D investment with a theoretical perspective, but few have conducted empirical studies. Therefore, we conduct a difference-in-differences (DID) model and use panel data of 111 A-share listed pharmaceutical firms from 2012 to 2020 to empirically study the impact of the consistency evaluation policy of generic drugs on pharmaceutical firms' R&D investment intensity. The result shows that the policy has a significant positive impact on the R&D investment intensity of firms with chemical generics, robust under the test for parallel trend test, placebo test, and the propensity score matching and difference-in-differences (PSM-DID) test. In addition, we further analyzed the impact of this policy on the R&D intensity of pharmaceutical firms according to the heterogeneity of enterprise's operational nature, regional distribution and profitability. From the perspective of time changes and the average effect, the R&D investment intensity of private pharmaceutical firms is more affected by the policy than state-owned enterprises; the R&D investment intensity of pharmaceutical firms in the eastern region is more affected by this policy than those in the central and the western; the R&D investment intensity of high-profitability pharmaceutical firms is more affected by the policy than those with low-profitability. The consistency evaluation policy is still being implemented, and its impact on pharmaceutical firms needs to be studied from different empirical research perspectives in the future.

25 August 2023 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Open access
PDF file
PLPei Li
Pei Li
SWSu Wang
Su Wang
YCYuwen Chen
Yuwen Chen
Real-world data (RWD) and real-world evidence (RWE) have garnered great interest for supporting drug research and development (R&D) by medical researchers and regulators in recent years. The application and development of RWD/E in drug regulatory decision-making have been vigorously promoted in China. This study seeks to provide a broad overview of how RWE has been contributing to drug regulatory decisions in China. In this paper, we review the development of RWD and RWE, summarize key elements that promote application of RWE, introduce relevant methods and guidelines, elaborate on the opportunities and challenges of RWE in regulatory decision-making in China, and put forward suggestions to promote the application of RWE in China’s regulatory decision-making and to further facilitate innovative drug evaluation and regulation.

14 April 2023 in Frontiers in Public Health
Verified
Journal Article
Open access
JZJialin Zhu
Jialin Zhu
YTYaning Tang
Yaning Tang
YWYanyi Wei
Yanyi Wei
SWSu Wang
Su Wang
YCYuwen Chen
Yuwen Chen
The relationship between financialization and innovation has become a common focus of academic attention. This paper analyzes the influence of corporate financialization on innovation efficiency based on balanced panel data of listed Chinese pharmaceutical companies from 2015 to 2020. Also, it examines the relationship between corporate financialization and innovation efficiency under different levels of financing constraints and the moderating mechanisms that exist. The results of the study show that corporate financialization negatively affects innovation efficiency and that this effect has a lag; corporate financialization hurts innovation efficiency across the different regions and firm nature, with a less inhibiting effect for eastern firms and non-state-owned firms; further tests of the mechanism of action show that there is a non-linear negative relationship between corporate financialization and innovation efficiency. And the inhibition of corporate financialization on innovation efficiency decreases as the level of financing constraints rises. Based on the above findings, this study provides warnings and recommendations for pharmaceutical companies to finance their innovative activities through financialization.

23 November 2023 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Open access
PDF file
PLPei Li
Pei Li
SWSu Wang
Su Wang
YCYuwen Chen
Yuwen Chen
Traditional Chinese medicine (TCM) is a valuable resource unique to China with a long history of human use and clinical practice, which can be analyzed to generate real-world evidence (RWE). The Chinese government has been actively promoting regulatory reform that is in line with the characteristics of TCM, optimizing the clinical evidence system for TCM, and exploring the important role of RWE in supporting the development of new drugs and regulatory decision-making for TCM. This article aims to provide a comprehensive review of the use of RWE in regulatory decisions for TCM. Based on the characteristics of TCM, this study focuses on the application scenarios, challenges, and opportunities of RWE in TCM. And some suggestions are put forward to promote the wider application of RWE in TCM development and supervision.

7 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SWSu Wang
Su Wang
QLQiang Liu
Qiang Liu
YCYuwen Chen
Yuwen Chen
Technology accumulation plays a vital role in research and development (R&D) activities. This paper used technology accumulation as the threshold variable to construct a dynamic panel threshold model to explore the technology accumulation threshold effect of independent R&D on innovation performance of China’s pharmaceutical manufacturing industry over the period 1995~2019. The results show that the independent R&D of China’s pharmaceutical manufacturing industry had a significant promotion effect on innovation performance. However, it is constrained by the level of technology accumulation, showing a significant double threshold effect of technology accumulation. A moderate level of technology accumulation was more conducive to independent R&D to drive innovation performance, while lower or higher technology accumulation will weaken independent R&D promotion on innovation performance. This study provided insights for policymakers and managers in making effective innovation strategies.